China's burgeoning biotech R&D capabilities are attracting increasing international attention, with non-Western countries ...

Chinese biotech Akeso (HKEX: 9926) has reported encouraging early data from a Phase III trial of its bispecific antibody ...

The New Drug Application (NDA) for Tazverik (tazemetostat) has been granted conditional approval in China for the treatment ...

Dizal Pharmaceutical will present new research findings on two of its innovative drugs - sunvozertinib and golidacitinib - at ...

US healthcare giant Johnson & Johnson has announced manufacturing, research and development and technology investments of ...

Monte Rosa Therapeutics, a US biotech developing novel molecular glue degrader (MGD)-based medicines, closed Thursday’s ...

US biotech Rhythm Pharmaceuticals (Nasdaq: RYTM) has reacquired the rights to its obesity treatment Imcivree (setmelanotide) ...

The US Food and Drug Administration (FDA) has approved Swiss pharma giant Novartis’ (NOVN: VX) oral Fabhalta (iptacopan) for ...

US pharma major Johnson & Johnson (NYSE: JNJ) has won US approval for Tremfya (guselkumab) in the treatment of adults with ...

US biotech GRO Biosciences is weighing the way forward for its lead gout program following a quiet restructuring that saw a ...

Japanese ophthalmology company Santen Pharmaceutical (TYO: 4536) announced that it will launch Ryjusea Mini solution 0.025% ...

UK pharma major AstraZeneca (LSE: AZN) today announced an investment of $2.5 billion in Beijing to establish its sixth global strategic R&D center, as well as major research and manufacturing ...